Vice President
Analysis Group, Inc., London, UK, United Kingdom
Marianne Cunnington is currently a Vice President in the Healthcare Practice at Analysis Group and has 20 years of experience working as an industry pharmacoepidemiologist leading real world benefit risk evidence generation activities. After working in public health infectious disease surveillance, Marianne joined GSK Pharma supporting a range of therapeutic areas and developing an interest in post marketing non-interventional medication safety studies, specifically in vulnerable groups such as pregnant women. She subsequently led the Epidemiology group at Novartis’ Vaccines Division completing several pandemic influenza vaccine safety studies and collaborated with public health agencies to deliver the post marketing safety and effectiveness programs for a new Meningitis B vaccine. Upon returning to GSK she led multiple therapy area groups within the Epidemiology team, chaired GSK Pharma’s protocol review committee responsible for the technical review of all real world studies across the pharma organisation, has led several long term academic partnerships and provided epidemiological expertise to GSK’s Global Safety Board with Epidemiology expertise. She holds a PhD in infectious disease epidemiology from the London School of Hygiene and Tropical Medicine.